Bortezomib with or without docetaxel has modest activity for refractory or recurrent advanced non-small-cell lung cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1565, 2006-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G   Peake M   Aultman R   Gyldmark M   Morlotti L   Creeden J   de la Orden M  

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite

Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

By Schuette W.  

Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. : 161-168

Adis International

Access to resources Recommend Favorite

The Vx 001 [TERT572Y] vaccine has shown promise in the treatment of advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1598, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The combination of irinotecan plus carboplatin has antitumour activity in non-small-cell lung cancer (NSCLC)

By  

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Vandetanib has value in non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite